Tarlatamab Clinical Trials (2026): 32 Studies for Small Cell Lung Cancer & Extensive Stage Small Cell Lung Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
32 Tarlatamab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 24 indications (including Small Cell Lung Cancer & Extensive Stage Small Cell Lung Cancer) and 4,380 total planned enrollment. 5 Phase 3 Tarlatamab trials and 15 Phase 2 are listed. 19 Tarlatamab clinical trials are actively recruiting at 84 U.S. sites across 28 states. Most recent activity: NCT06898957 (Jun 2031).
Where to Participate: All Tarlatamab Trial Sites in the U.S. (84 sites across 28 states)
Every actively recruiting Tarlatamabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Cancer and Blood Specialists of Arizona | Casa Grande85222 | NCT07005128 | Map |
| AZ | Banner MD Anderson Cancer Center | Gilbert85234 | NCT07037758 | Map |
| AZ | City of Hope Cancer Center Phoenix | Goodyear85338 | NCT07005128 | Map |
| AZ | Arizona Cancer Center at UMC North/University Medical Center | Tucson85719 | NCT06814496 | Map |
| AR | Genesis Cancer Center | Hot Springs71913 | NCT07005128 | Map |
| AR | Saint Bernards Medical Center | Jonesboro72401 | NCT07005128 | Map |
| CA | UC Davis Comprehensive Cancer Center | Davis95817 | NCT06788938 | Map |
| CA | UCI Health Chao Family Comprehensive Cancer Center | Irvine92612 | NCT06788938 | Map |
| CA | Translational Research in Oncology US Inc, Trio Central Pharmacy | Los Angeles90095 | NCT07005128 | Map |
| CA | University of California at Los Angeles | Los Angeles90095 | NCT06788938 | Map |
| CA | University of Southern California, Norris Comprehensive Cancer Center | Los Angeles90033 | NCT06598306 | Map |
| CA | University of Southern California, Norris Comprehensive Cancer Center | Los Angeles90033 | NCT07037758 | Map |
| CA | UC San Diego Moores Cancer Center | San Diego92093 | NCT06788938 | Map |
| CA | UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only) | San Diego92103 | NCT07111507 | Map |
| CA | University of California at San Francisco | San Francisco94143 | NCT06788938 | Map |
| CA | University of California San Francisco | San Francisco94143 | NCT07111507 | Map |
| CA | University of California Los Angeles | Santa Monica90404 | NCT07005128 | Map |
| CA | Presbyterian Intercommunity Hospital Health Whitter Hospital | Whittier90602 | NCT07005128 | Map |
| CO | Colorado West Healthcare System dba Grand Valley Oncology | Grand Junction81505 | NCT07005128 | Map |
| CT | Yale New Haven Hospital | New Haven06510 | NCT07005128 | Map |
| CT | Eastern Connecticut Hematology and Oncology Associates | Norwich06360 | NCT07005128 | Map |
| FL | Cancer Specialists of North Florida - Southpoint | Jacksonville32256 | NCT07005128 | Map |
| FL | Orlando Health Cancer Institute | Kissimmee34744 | NCT07005128 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT07037758 | Map |
| GA | Emory University | Atlanta30322 | NCT07037758 | Map |
| GA | City of Hope Atlanta | Newnan30265 | NCT07005128 | Map |
| IL | University of Illinois Chicago | Chicago60612 | NCT06598306 | Map |
| IL | University of Illinois Chicago | Chicago60612 | NCT07005128 | Map |
| IL | Cancer Care Specialists of Illinois | Decatur62526 | NCT07005128 | Map |
| IL | Midwestern Regional Medical Center dba City of Hope Chicago | Rockford61108 | NCT07005128 | Map |
| IN | Hematology Oncology of Indiana | Indianapolis46260 | NCT07005128 | Map |
| IN | Indiana University Melvin and Bren Simon Cancer Center | Indianapolis46202 | NCT07005128 | Map |
| KS | Cancer Center of Kansas, Heritage Plaza Medical Building | Wichita67214 | NCT07005128 | Map |
| KY | Norton Cancer Institute - Downtown | Louisville40202-1703 | NCT07037758 | Map |
| ME | New England Cancer Specialists | Westbrook04092 | NCT07005128 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT07005128 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT07037758 | Map |
| MI | Trinity Health Saint Joseph Mercy Ann Arbor | Ann Arbor48106 | NCT06598306 | Map |
| MN | Minnesota Oncology Hematology PA | Edina55435 | NCT07005128 | Map |
| MN | Allina Health System dba Allina Health Cancer Institute | Minneapolis55407 | NCT07005128 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT07005128 | Map |
| MO | Siteman Cancer Center | St Louis63110 | NCT07037758 | Map |
| NE | Cancer Partners of Nebraska | Lincoln68516 | NCT07005128 | Map |
| NE | Nebraska Cancer Specialists | Omaha68130 | NCT07005128 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT07111507 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT07111507 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT07111507 | Map |
| NY | New York Oncology Hematology PC | Albany12206 | NCT07005128 | Map |
| NY | Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) | Commack11725 | NCT07111507 | Map |
| NY | Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison10604 | NCT07111507 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10021 | NCT07037758 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT07111507 | Map |
| NY | New York University Cancer Institute | New York10016 | NCT07531095 | Map |
| NY | New York Cancer and Blood Specialists | Shirley11967 | NCT07005128 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale11553 | NCT07111507 | Map |
| OH | Oncology Hematology Care, Inc | Cincinnati45242 | NCT07005128 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT07005128 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT07423585 | Map |
| OR | Willamette Valley Cancer Institute and Research Center - Eugene | Eugene97401 | NCT07005128 | Map |
| OR | Kaiser Permanente Medical Center | Portland97227 | NCT07005128 | Map |
| PA | Sidney Kimmel Cancer Center | Philadelphia19107 | NCT07037758 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT07111507 | Map |
| PA | Allegheny General Hospital | Pittsburgh15212 | NCT07037758 | Map |
| SD | Avera Cancer Institute | Sioux Falls57105 | NCT06598306 | Map |
| SD | Avera Cancer Institute | Sioux Falls57105 | NCT07037758 | Map |
| TN | Baptist Cancer Center | Memphis38120 | NCT07005128 | Map |
| TN | Baptist Cancer Center | Memphis38120 | NCT07037758 | Map |
| TN | Baptist Cancer Center | Memphis38120 | NCT07531095 | Map |
| TN | United States Oncology Regulatory Affairs Corporate Office | Nashville37203 | NCT07005128 | Map |
| TX | Texas Oncology - Dallas Fort Worth | Dallas75246 | NCT07005128 | Map |
| TX | Oncology Consultants | Houston77030 | NCT07005128 | Map |
| TX | University of Texas MD Anderson Cancer Center | Houston77030 | NCT06598306 | Map |
| TX | US Oncology Research Investigational Products Center | Irving75063 | NCT07005128 | Map |
| TX | Texas Oncology Northeast Texas | Tyler75702 | NCT07005128 | Map |
| TX | University of Texas Health Science Center at Tyler | Tyler75701 | NCT07005128 | Map |
| VA | Next Virginia | Fairfax22031 | NCT07531095 | Map |
| VA | Virginia Cancer Specialists PC | Fairfax22031 | NCT07005128 | Map |
| VA | Virginia Oncology Associates | Norfolk23502 | NCT07005128 | Map |
| WA | Swedish Cancer Institute | Seattle98104 | NCT06598306 | Map |
| WA | Swedish Cancer Institute Medical Oncology | Seattle98104 | NCT07005128 | Map |
| WA | Swedish Cancer Institute Medical Oncology | Seattle98109 | NCT07037758 | Map |
| WA | University of Washington Fred Hutchinson Cancer Center | Seattle98109 | NCT06814496 | Map |
| WA | Northwest Medical Specialties, PLLC | Tacoma98405 | NCT07005128 | Map |
| WV | West Virginia University Health Sciences Center | Morgantown26506 | NCT07005128 | Map |
Tarlatamab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | withdrawn | not yet recruiting | approved for marketing | Total |
|---|---|---|---|---|---|---|---|
| P1 | 3 | 3 | 2 | 8 | |||
| P1/P2 | 2 | 1 | 3 | ||||
| P2 | 10 | 3 | 2 | 15 | |||
| P3 | 2 | 3 | 5 | ||||
| N/A | 1 | 1 |
Recruiting Tarlatamab clinical trials (19)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07531095 | DeLLphi-313Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) | P1 | Small Cell Lung Cancer | 160 | Apr 2026 |
| NCT07037758 | DeLLphi-311A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) | P1 | Extensive Stage Small Cell Lung Cancer | 380 | Sep 2025 |
| NCT07243470 | TARLATEMCombination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors | P1/P2 | Glioma | 70 | Nov 2025 |
| NCT06937905 | TARLANECTarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) | P3 | Neuroendocrine Carcinoma | 129 | Feb 2026 |
| NCT07242547 | MERLINStudy of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients | P2 | Limited-stage Small-cell Lung Cancer | 37 | May 2026 |
| NCT06814496 | RABBITRadiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors | P1/P2 | Melanoma | 30 | Sep 2025 |
| NCT06598306 | DeLLphi-308Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) | P1 | Extensive Stage Small Cell Lung Cancer | 220 | Oct 2024 |
| NCT07402343 | T-BRAINTarlatamab for SCLC Brain Metastases | P2 | Small Cell Lung Cancer | 35 | May 2026 |
| NCT07016230 | AMG 757Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB) | P2 | Metastatic/Locally Advanced Small-Cell Lung Cancer | 40 | Jul 2025 |
| NCT07203053 | START-lungA Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 | P2 | Extensive Stage Lung Small Cell Cancer | 48 | Apr 2026 |
| NCT07005128 | DeLLphi-312A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) | P3 | Small-cell Lung Cancer | 330 | Aug 2025 |
| NCT06893783 | DeLLightEfficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients | P2 | Neuroendocrine Carcinomas (NEC) | 60 | Sep 2025 |
| NCT06816394 | TAURUSTarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS) | P2 | Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma | 32 | May 2025 |
| NCT06788938 | DLL3Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms | P2 | DLL3-expressing Tumors | 29 | Mar 2025 |
| NCT07061080 | RAGNARRefractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab | P2 | Advanced Neuroendocrine Carcinomas of The Digestive System | 87 | Dec 2025 |
| NCT06776250 | Study of How Safe and Effective Tarlatamab is in Brain Cancers | P2 | Astrocytic Tumor | 44 | Aug 2025 |
| NCT07423585 | Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer | P2 | Extensive Stage Lung Small Cell Carcinoma | 39 | Apr 2026 |
| NCT07111507 | A Study of Tarlatamab for People With Prostate Cancer | P2 | Metastatic Prostate Cancer | 32 | Jul 2025 |
| NCT06830694 | AMG757Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment | P2 | Small Cell Carcinoma of Lung | 50 | May 2025 |
Tarlatamab clinical trials by indication
Small Cell Lung Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06898957 | (DeLLphi-310) | P1 | active not recruiting | Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) |
| NCT07531095 | DeLLphi-313 | P1 | recruiting | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) |
| NCT07402343 | T-BRAIN | P2 | not yet recruiting | Tarlatamab for SCLC Brain Metastases |
| NCT04885998 | SCLC | P1 | completed | AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) |
| NCT06064500 | AMG 757 | N/A | approved for marketing | Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer |
Extensive Stage Small Cell Lung Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07037758 | DeLLphi-311 | P1 | recruiting | A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) |
| NCT06598306 | DeLLphi-308 | P1 | recruiting | Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) |
| NCT05361395 | ES-SCLC | P1 | active not recruiting | First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) |
| NCT06502977 | DeLLphi-307 | P2 | active not recruiting | Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment |
Small Cell Lung Cancer (SCLC) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06745323 | DeLLphi-309 | P2 | active not recruiting | A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC |
| NCT05740566 | DeLLphi-304 | P3 | active not recruiting | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer |
Extensive Stage Lung Small Cell Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07203053 | START-lung | P2 | recruiting | A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 |
Extensive-Stage Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07328490 | — | P1/P2 | withdrawn | Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer |
Extensive Stage Lung Small Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07423585 | — | P2 | recruiting | Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer |
Limited-stage Small-cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07242547 | MERLIN | P2 | recruiting | Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients |
Neuroendocrine Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06937905 | TARLANEC | P3 | recruiting | Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) |
Advanced Neuroendocrine Carcinomas of The Digestive System (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07061080 | RAGNAR | P2 | recruiting | Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab |
Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07243470 | TARLATEM | P1/P2 | recruiting | Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors |
Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06814496 | RABBIT | P1/P2 | recruiting | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors |
Neuroendocrine Carcinomas (NEC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06893783 | DeLLight | P2 | recruiting | Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients |
Astrocytic Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06776250 | — | P2 | recruiting | Study of How Safe and Effective Tarlatamab is in Brain Cancers |
Small-cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07005128 | DeLLphi-312 | P3 | recruiting | A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) |
Metastatic Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07111507 | — | P2 | recruiting | A Study of Tarlatamab for People With Prostate Cancer |
Metastatic/Locally Advanced Small-Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07016230 | AMG 757 | P2 | recruiting | Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB) |
Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06816394 | TAURUS | P2 | not yet recruiting | Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS) |
Small Cell Carcinoma of Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06830694 | AMG757 | P2 | recruiting | Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment |
DLL3-expressing Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06788938 | DLL3 | P2 | recruiting | Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms |
Extensive-Stage Small-Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06211036 | DeLLphi-305 | P3 | active not recruiting | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab |
Limited Stage Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06117774 | DeLLphi-306 | P3 | active not recruiting | Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) |
Relapsed/Refractory Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05060016 | DeLLphi-301 | P2 | active not recruiting | A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) |
Neuroendocrine Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04702737 | DeLLpro-300 | P1 | completed | A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer |
Small Cell Lung Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03319940 | PK | P1 | active not recruiting | Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) |
Tarlatamab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| TARLANEC | NCT06937905 | P3 | recruiting | Neuroendocrine Carcinoma | 129 | — |
| DeLLphi-306 | NCT06117774 | P3 | active not recruiting | Limited Stage Small Cell Lung Cancer | 404 | — |
| DeLLphi-312 | NCT07005128 | P3 | recruiting | Small-cell Lung Cancer | 330 | — |
| DeLLphi-305 | NCT06211036 | P3 | active not recruiting | Extensive-Stage Small-Cell Lung Cancer | 563 | — |
| DeLLphi-304 | NCT05740566 | P3 | active not recruiting | Small Cell Lung Cancer (SCLC) | 509 | — |
| MERLIN | NCT07242547 | P2 | recruiting | Limited-stage Small-cell Lung Cancer | 37 | — |
| T-BRAIN | NCT07402343 | P2 | not yet recruiting | Small Cell Lung Cancer | 35 | — |
| AMG 757 | NCT07016230 | P2 | recruiting | Metastatic/Locally Advanced Small-Cell Lung Cancer | 40 | — |
| START-lung | NCT07203053 | P2 | recruiting | Extensive Stage Lung Small Cell Cancer | 48 | — |
| DeLLight | NCT06893783 | P2 | recruiting | Neuroendocrine Carcinomas (NEC) | 60 | — |
| TAURUS | NCT06816394 | P2 | not yet recruiting | Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma | 32 | — |
| DLL3 | NCT06788938 | P2 | recruiting | DLL3-expressing Tumors | 29 | — |
| DeLLphi-309 | NCT06745323 | P2 | active not recruiting | Small Cell Lung Cancer (SCLC) | 252 | — |
| RAGNAR | NCT07061080 | P2 | recruiting | Advanced Neuroendocrine Carcinomas of The Digestive System | 87 | — |
| DeLLphi-301 | NCT05060016 | P2 | active not recruiting | Relapsed/Refractory Small Cell Lung Cancer | 222 | — |
| AMG757 | NCT06830694 | P2 | recruiting | Small Cell Carcinoma of Lung | 50 | — |
| DeLLphi-307 | NCT06502977 | P2 | active not recruiting | Extensive Stage Small Cell Lung Cancer | 32 | — |
Terminated and withdrawn Tarlatamab trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT07328490withdrawnBispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
All Tarlatamab trials (32)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06898957 | (DeLLphi-310) | Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) | P1 | active not recruiting | 29 | Amgen | May 2025 |
| NCT07531095 | DeLLphi-313 | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) | P1 | recruiting | 160 | Amgen | Apr 2026 |
| NCT07037758 | DeLLphi-311 | A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) | P1 | recruiting | 380 | Amgen | Sep 2025 |
| NCT07243470 | TARLATEM | Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors | P1/P2 | recruiting | 70 | Centre Leon Berard | Nov 2025 |
| NCT06937905 | TARLANEC | Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) | P3 | recruiting | 129 | Intergroupe Francophone de Cancerologie Thoracique | Feb 2026 |
| NCT07242547 | MERLIN | Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients | P2 | recruiting | 37 | Fundación GECP | May 2026 |
| NCT06814496 | RABBIT | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors | P1/P2 | recruiting | 30 | University of Arizona | Sep 2025 |
| NCT06598306 | DeLLphi-308 | Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) | P1 | recruiting | 220 | Amgen | Oct 2024 |
| NCT06117774 | DeLLphi-306 | Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) | P3 | active not recruiting | 404 | Amgen | Feb 2024 |
| NCT07402343 | T-BRAIN | Tarlatamab for SCLC Brain Metastases | P2 | not yet recruiting | 35 | Maastricht University Medical Center | May 2026 |
| NCT07016230 | AMG 757 | Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB) | P2 | recruiting | 40 | Gustave Roussy, Cancer Campus, Grand Paris | Jul 2025 |
| NCT07203053 | START-lung | A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 | P2 | recruiting | 48 | ETOP IBCSG Partners Foundation | Apr 2026 |
| NCT07005128 | DeLLphi-312 | A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) | P3 | recruiting | 330 | Amgen | Aug 2025 |
| NCT06893783 | DeLLight | Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients | P2 | recruiting | 60 | Inkeun Park | Sep 2025 |
| NCT06816394 | TAURUS | Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS) | P2 | not yet recruiting | 32 | National Taiwan University Hospital | May 2025 |
| NCT06788938 | DLL3 | Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms | P2 | recruiting | 29 | Jonsson Comprehensive Cancer Center | Mar 2025 |
| NCT06745323 | DeLLphi-309 | A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC | P2 | active not recruiting | 252 | Amgen | Feb 2025 |
| NCT07061080 | RAGNAR | Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab | P2 | recruiting | 87 | Grupo Espanol de Tumores Neuroendocrinos | Dec 2025 |
| NCT06211036 | DeLLphi-305 | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab | P3 | active not recruiting | 563 | Amgen | Jun 2024 |
| NCT05361395 | ES-SCLC | First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | P1 | active not recruiting | 184 | Amgen | Aug 2022 |
| NCT05740566 | DeLLphi-304 | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer | P3 | active not recruiting | 509 | Amgen | May 2023 |
| NCT06776250 | Study of How Safe and Effective Tarlatamab is in Brain Cancers | P2 | recruiting | 44 | University Health Network, Toronto | Aug 2025 | |
| NCT07423585 | Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer | P2 | recruiting | 39 | Asrar Alahmadi | Apr 2026 | |
| NCT03319940 | PK | Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) | P1 | active not recruiting | 269 | Amgen | Dec 2017 |
| NCT05060016 | DeLLphi-301 | A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) | P2 | active not recruiting | 222 | Amgen | Dec 2021 |
| NCT07111507 | A Study of Tarlatamab for People With Prostate Cancer | P2 | recruiting | 32 | Memorial Sloan Kettering Cancer Center | Jul 2025 | |
| NCT06830694 | AMG757 | Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment | P2 | recruiting | 50 | Se-Hoon Lee | May 2025 |
| NCT06502977 | DeLLphi-307 | Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment | P2 | active not recruiting | 32 | Amgen | Aug 2024 |
| NCT07328490 | Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer | P1/P2 | withdrawn | 0 | National Cancer Institute (NCI) | Apr 2026 | |
| NCT04885998 | SCLC | AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) | P1 | completed | 23 | Amgen | Sep 2021 |
| NCT04702737 | DeLLpro-300 | A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer | P1 | completed | 41 | Amgen | Jun 2021 |
| NCT06064500 | AMG 757 | Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer | — | approved for marketing | 0 | Amgen | — |
Tarlatamab clinical trials: frequently asked questions
- How many Tarlatamab clinical trials are there?
- 32 Tarlatamab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 17 are actively recruiting participants. 2 are marked completed.
- Are Tarlatamab clinical trials recruiting in 2026?
- Yes — 17 Tarlatamab trials are actively recruiting in 2026, with 84 U.S. sites across 28 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Tarlatamab being studied for?
- Tarlatamab is being studied for Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer, Small Cell Lung Cancer (SCLC), Astrocytic Tumor, Bladder Cancer and 46 more. The trials are grouped by indication on this page.
- What phase is Tarlatamab in?
- Tarlatamab clinical trials span 5 Phase 3, 15 Phase 2, 8 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Tarlatamab clinical trials?
- The lead sponsor across the most Tarlatamab trials is Amgen, with 16 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Tarlatamabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: